Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Biogen is the lead sponsor of 37 current clinical trials in our USA, UK, China, India and Ireland registers. 18 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Felzartamab, Litifilimab and Omaveloxolone. The most-studied condition is Muscular Atrophy, Spinal.

Company profile on this site (news, sites, medicines, approvals): Biogen (US) →

ClinicalTrials.gov trials by status

Recruiting1849%
Active, closed1643%
By invitation38%

Trials by phase

Phase 31541%
Observational1130%
Phase 1616%
Phase 238%
Phase 2/313%
Phase 413%

Clinical trials sponsored by Biogen

37 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia NCT06953583 · Friedreich Ataxia Drug: Omaveloxolone	Phase 3	Recruiting	2025-06	Ireland, UK, USA, India
A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old NCT07133828 · Healthy Volunteer	Phase 1	Recruiting	2025-08	USA
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) NCT06935357 · Immunoglobulin A Nephropathy (IgAN) Drug: Felzartamab	Phase 3	Recruiting	2025-05	UK, USA, India, China
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) NCT05658497 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drugs: Dimethyl Fumarate, Diroximel Fumarate, Tysabri	Observational	Recruiting	2023-10	Ireland, UK, USA
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) NCT06962800 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy Drugs: Felzartamab, Tacrolimus	Phase 3	Recruiting	2025-05	USA, India, China
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone NCT07398469 · Postpartum Depression	Observational	Recruiting	2025-12	USA
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) NCT07221669 · Muscular Atrophy, Spinal Drug: Salanersen	Phase 3	Recruiting	2026-04	USA, China
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) NCT06555419 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal Drug: Nusinersen	Phase 1	Recruiting	2025-01	UK, USA
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies NCT05789758 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal	Observational	Recruiting	2023-12	UK, USA
A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants NCT07225517 · ClinicalTrials.gov ↗ · Healthy Volunteer	Phase 1	Recruiting	2025-12	USA
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation NCT07219043 · ClinicalTrials.gov ↗ · Microvascular Inflammation Drug: Felzartamab	Phase 2	Recruiting	2026-01	USA
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec NCT07444450 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal Drug: Salanersen	Phase 3	Recruiting	2026-09	USA
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam NCT07444476 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy Drug: Salanersen	Phase 3	Recruiting	2026-04	USA
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors NCT06623890 · ClinicalTrials.gov ↗ · Friedreich Ataxia Drug: Omaveloxolone	Observational	Recruiting	2024-12	USA
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) NCT07259980 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis Drug: Tofersen	Observational	Recruiting	2026-01	USA
A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo NCT07662148 · ClinicalTrials.gov ↗ · Healthy Volunteer	Phase 1	Recruiting	2026-07	USA
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old NCT07722546 · ClinicalTrials.gov ↗ · Graves' Disease Drug: Felzartamab	Phase 2	Recruiting	2026-07	USA
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies NCT06628687 · ClinicalTrials.gov ↗ · Friedreich Ataxia Drug: Omaveloxolone	Observational	Recruiting	2026-10	USA
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus NCT06044337 · ClinicalTrials.gov ↗ · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus Drug: Litifilimab	Phase 3	By invitation	2023-10	UK, USA, China
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) NCT05352919 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE) Drug: Litifilimab	Phase 3	By invitation	2022-06	UK, USA, China
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) NCT07444489 · ClinicalTrials.gov ↗ · Antibody-mediated Rejection, Microvascular Inflammation Drug: Felzartamab	Phase 3	By invitation	2026-04	USA
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus NCT04961567 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic Drug: Litifilimab	Phase 3	Active, closed	2021-07	UK, USA, China
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation NCT04856982 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation Drug: Tofersen	Phase 3	Active, closed	2021-05	UK, USA
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age NCT05399888 · ClinicalTrials.gov ↗ · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia	Phase 2	Active, closed	2022-08	UK, USA
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus NCT05531565 · ClinicalTrials.gov ↗ · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus Drug: Litifilimab	Phase 2/3	Active, closed	2022-09	UK, USA, China
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec NCT05575011 · ClinicalTrials.gov ↗ · Healthy Volunteer, Muscular Atrophy, Spinal	Phase 1	Active, closed	2022-10	UK
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) NCT05925049 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drug: Natalizumab	Observational	Active, closed	2023-06	USA
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus NCT04895241 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic Drug: Litifilimab	Phase 3	Active, closed	2021-05	USA
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) NCT07223723 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis Drug: Tofersen	Phase 4	Active, closed	2025-12	China
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) NCT05067790 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy Drug: Nusinersen	Phase 3	Active, closed	2022-01	USA
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis NCT03958877 · ClinicalTrials.gov ↗ · Multiple Sclerosis, Relapsing-Remitting Drug: Peginterferon beta-1a	Phase 3	Active, closed	2019-10	USA
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies NCT05688436 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drugs: Alemtuzumab, Diroximel Fumarate, Fingolimod	Observational	Active, closed	2021-09	USA
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) NCT05767736 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drugs: Dimethyl Fumarate, Diroximel Fumarate	Observational	Active, closed	2024-06	USA
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old NCT06054893 · ClinicalTrials.gov ↗ · Friedreich Ataxia Drug: Omaveloxolone	Phase 1	Active, closed	2024-07	USA
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) NCT06685757 · ClinicalTrials.gov ↗ · Antibody-mediated Rejection Drug: Felzartamab	Phase 3	Active, closed	2024-12	USA
Pediatric Spinal Muscular Atrophy (SMA) China Registry NCT05042921 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal	Observational	Active, closed	2021-11	China
Adult Spinal Muscular Atrophy (SMA) China Registry NCT05618379 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal	Observational	Active, closed	2023-01	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Biogen trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Felzartamab6 Litifilimab5 Omaveloxolone4 Diroximel Fumarate3 Salanersen3 Tofersen3 Dimethyl Fumarate2 Natalizumab2 Nusinersen2 Peginterferon beta-1a2 Tysabri2 Alemtuzumab1 Fingolimod1 Ocrelizumab1 Ofatumumab1 Ozanimod1 Ponesimod1 Siponimod1 Tacrolimus1

Conditions in Biogen trials

20 conditions

Muscular Atrophy, Spinal7Friedreich Ataxia4 Multiple Sclerosis4 Healthy Volunteer4 Lupus Erythematosus, Systemic2Subacute Cutaneous Lupus Erythematosus2Chronic Cutaneous Lupus Erythematosus2Antibody-mediated Rejection2Microvascular Inflammation2Spinal Muscular Atrophy2Amyotrophic Lateral Sclerosis2Immunoglobulin A Nephropathy (IgAN)1Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation1Mild Cognitive Impairment Due to Alzheimer's Disease1Alzheimer's Disease Dementia1Systemic Lupus Erythematosus (SLE)1Postpartum Depression1Multiple Sclerosis, Relapsing-Remitting1Graves' Disease1 Primary Membranous Nephropathy1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	33	18
Clinical trials in UK	12	5
Clinical trials in China	10	3
Clinical trials in India	3	3
Clinical trials in Ireland	2	2

A trial with sites in more than one country appears in each of those registers.

Questions about Biogen trials

How many clinical trials does Biogen sponsor?

Biogen is the lead sponsor of 37 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Biogen trials recruiting?

Yes. 18 of its 37 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Biogen testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Felzartamab (6), Litifilimab (5), Omaveloxolone (4), Diroximel Fumarate (3) and Salanersen (3). The number in brackets is how many of its trials name each drug.

Does Biogen have clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Biogen clinical trials